Completed PHASE1 INTERVENTIONAL 3-arm NCT01485952

An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 (PADDINGTON)

An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196.

Sponsor: European Huntington's Disease Network

Conditions Huntington Disease

Interventions Placebo SEN0014196 (High Dose) SEN0014196 (Low Dose)

Updated 5 times since 2017 Last updated: Nov 24, 2015 Started: Mar 31, 2011 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Huntington Disease, this trial is completed. The trial is conducted by European Huntington's Disease Network and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Huntington's Disease Network
Seventh Framework Programme
Siena Biotech S.p.A.

Data source: Siena Biotech S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulm, Germany